Apply for a consultation
Apply for a consultation
Apply for a consultation

Diagnoses for tumour treatment

  • Home
  • Diagnoses for tumour treatment

The CyberKnife System is most often used with a success to treat patients suffering from malignant and benign tumours, vascular malformations and other similar conditions. To find out if your condition can be treated with CyberKnife® M6 System, ask our specialists We are ready to help you! 

CyberKnife  is routinely used both as an alternative for a surgery or conventional radiotherapy and as the only treatment option for patients suffering from oncology and non-oncology pathologies. Often radiosurgery with the CyberKnife is combined both with surgical treatment and other treatment methods — chemotherapy, immunotherapy and radiotherapy. 

The CyberKnife®M6 System is especially suitable for treatment of cancerous and non-cancerous tumours located near vital organs and critical structures (such as optical, acoustic, facial nerves; brainstem, spinal cord etc.) In such situations a fractionated radiation mode is applied, i.e. the entire radiation dose is split into 3 to 5 radiosurgery sessions.

CyberKnife can be used to treat benign and malignant tumours and other malformations in the following body parts:


  • Benign brain tumours (Acoustic neuroma, Meningioma, pituitary adenoma);
  • Vascular malformations in brain (cavernoma, angioma, arteriovenous malformation);
  • Separate (1-4, up to 10) metastases in the brain from breast, lung, intestinal, prostate, kidney cancer, lymphoma and melanoma and other tumours;
  • Malignant tumours in the brain (low-grade gliomas — astrocytoma, oligodendroglioma after previous surgical treatment; stage I-II ependymoma; craniopharyngioma; hemangioma, hemangioblastoma, chordoma);
  • Trigeminal neuralgia;
  • Eye tumours (uveal melanoma and meningioma);
  • Tumours in the head and neck area (primary throat and vocal fold cancer, in combination with radiotherapy or surgery, repeated radiation of local recurrences).


  • Separate (1-4) metastases in the spine from tumours localised elsewhere;
  • Primary tumours in the spine and spinal cord (neurinoma, neurofibromatosis, meningioma, ependymoma, hemangioma).


  • Separate (1-4) metastases in the bones, spine, thorax from tumours localised elsewhere.


  • Separate (1-4) metastases in the lungs from tumours localised elsewhere;
  • Peripheral or centrally located non-small cell lung cancer.

Gastrointestinal tract

  • Primary liver cancer (< 4 cm);
  • Separate (1-4) metastases in the liver from tumours localised elsewhere;
  • Pancreatic cancer.

Genitourinary system

  • Primary renal cancer or individual metastases (1-4);
  • Primary prostate cancer;
  • Recurrent prostate cancer or oligometastatic prostate cancer (1-4 metastases).

2021 - © Consilium Veritas